ArticleBiosensors2025
Electrochemical Determination of Doxorubicin in the Presence of Dacarbazine Using MWCNTs/ZnO Nanocomposite Modified Disposable Screen-Printed Electrode.
Article in Biosensors, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Article
- Epirubicin-sensitive detection with a CoWOADMET & DMPK · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
In the current work, the MWCNTs/ZnO nanocomposite was successfully synthesized using simple method. Then, FE-SEM, XRD, and EDX techniques were applied for morphological and structural characterization. Afterward, a sensitive voltammetric sensor based on modification of a screen-printed carbon electrode (SPCE) using MWCNTs/ZnO nanocomposite was developed for the determination of doxorubicin in the presence of dacarbazine. To evaluate the electrochemical response of the MWCNTs/ZnO/SPCE towards doxorubicin, cyclic voltammetry (CV) was applied. The MWCNTs/ZnO nanocomposite showed a significant synergistic effect on the electrochemical response of the electrode for the redox reaction of doxorubicin. Also, the MWCNTs/ZnO/SPCE demonstrated an enhanced sensing platform for the quantification of doxorubicin, obtaining a detection limit (LOD) of 0.002 µM and a sensitivity of 0.0897 µA/µM, as determined by differential pulse voltammetry (DPV) within a linear range from 0.007 to 150.0 µM. Also, the MWCNTs/ZnO nanocomposite-modified SPCE showed high electrochemical activities towards the oxidation of doxorubicin and dacarbazine with peak-potential separation of 345 mV, which is sufficient for doxorubicin determination in the presence of dacarbazine. Also, the MWCNTs/ZnO nanocomposite-modified SPCE presented reproducible and stable responses to determine doxorubicin. Finally, the developed platform demonstrated a successful performance for doxorubicin and dacarbazine determination in real samples, with recovery in the range of 97.1% to 104.0% and relative standard deviation (RSD) from 1.8% to 3.5%.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.